Histone deacetylase inhibitors in programmed cell death and cancer therapy Journal Article


Authors: Marks, P. A.; Jiang, X.
Article Title: Histone deacetylase inhibitors in programmed cell death and cancer therapy
Abstract: Histone deacetylase (HDAC) inhibitors, such as suberoylanilide hydroxamic acid (SAHA), are targeted anticancer agents that have significant anticancer activity at doses well tolerated by patients.1 Recently, we found that HDAC inhibitors can trigger both mitochondria-mediated apoptosis and caspase-independent autophagic cell death, indicating potential benefit of HDAC inhibitors in treating cancers with apoptotic defects.2 We also found that thioredoxin (TRX) might play a significant role in HDAC inhibitor-induced cell death, and HDAC inhibitors increase TRX levels in normal cells but not transformed cells, which is likely to be one of the reasons why HDAC inhibitors preferentially kill cancer cells.3 In this review, we discuss the study of HDAC inhibitors in cell death and cancer research, the implications of our recent findings, and some outstanding questions that need to be addressed. ©2005 Landes Bioscience.
Keywords: cancer chemotherapy; unclassified drug; histone deacetylase inhibitor; clinical trial; drug activity; drug tolerability; nonhuman; antineoplastic agents; antineoplastic agent; neoplasms; apoptosis; antineoplastic activity; drug potency; drug structure; caspase; cancer research; cancer therapy; gene expression regulation, neoplastic; enzyme inhibitors; cell transformation; cancer cell; vorinostat; hydroxamic acids; reactive oxygen species; short survey; autophagy; mitochondria; histone deacetylases; mitochondrion; cell killing; n (2 aminophenyl) 4 (3 pyridinylmethoxycarbonylaminomethyl)benzamide; butyric acid; cytostatic agent; thioredoxin; hdac inhibitors; autophagic cell death; trapoxin a
Journal Title: Cell Cycle
Volume: 4
Issue: 4
ISSN: 1538-4101
Publisher: Taylor & Francis Inc.  
Date Published: 2005-04-01
Start Page: 549
End Page: 551
Language: English
PUBMED: 15738652
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 91" - "Export Date: 24 October 2012" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Xuejun Jiang
    121 Jiang
  2. Paul Marks
    186 Marks
Related MSK Work